

Italia Grenga

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11845348/italia-grenga-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

1,216
citations

17
h-index

23
g-index

23
ext. papers

1,500
ext. citations

7.7
avg, IF

3.87
L-index

#	Paper	IF	Citations
23	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1287-1295	12.9	195
22	Anti-PD-L1/TGFβ2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 93.e1-93.e11	2.8	23
21	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody 2017 , 5, 20		57
20	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology, The</i> , 2017 , 18, 587-598	21.7	194
19	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017 , 23, 6833-6845	12.9	39
18	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016 , 5, 5	3.3	34
17	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. <i>Onc Immunology</i> , 2016 , 5, e1188243	7.2	20
16	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016 , 7, 69014-69023	3.3	31
15	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016 , 7, 37762-37772	3.3	76
14	A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. <i>Clinical and Translational Immunology</i> , 2016 , 5, e83	6.8	38
13	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 755-65	12.5	25
12	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015 , 3, 1248-56	12.5	89
11	Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses 2015 , 3, P132		4
10	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack 2015 , 3, 52		14
9	Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression 2015 , 3, P253		78
8	Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells 2015 , 3, P254		78
7	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 1087-95	13.4	58

6	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3055-3055	2.2	14
5	Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. <i>Cancer Immunology Research</i> , 2014 , 2, 1090-102	12.5	51
4	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). <i>Medical Oncology</i> , 2013 , 30, 743	3.7	14
3	Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study. <i>Supportive Care in Cancer</i> , 2012 , 20, 2713-20	3.9	6
2	An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 931-2	7	15
1	Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. <i>International Journal of Colorectal Disease</i> , 2011 , 26, 143-51	3	63